Melanoma and other skin tumours
Invited discussant abstracts 1112PD, 1113PD and 1114PD
Date
10 Oct 2016Session
Melanoma and other skin tumoursPresenters
Christian BlankAuthors
C.U. BlankAuthor affiliations
- Medical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, 1066 CX - Amsterdam/NL
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
4587 - (Neo-)adjuvant ipilimumab + nivolumab (IPI + NIVO) in palpable stage 3 melanoma – initial data from the OpACIN trial
Presenter: Christian Blank
Session: Melanoma and other skin tumours
Resources:
Abstract
Slides
3696 - Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma
Presenter: Caroline Robert
Session: Melanoma and other skin tumours
Resources:
Abstract
Slides
2037 - Genomic features of complete responders (CR) versus fast progressors (PD) in patients with BRAFV600-mutated metastatic melanoma treated with cobimetinib + vemurafenib or vemurafenib alone
Presenter: Antoni Ribas
Session: Melanoma and other skin tumours
Resources:
Abstract
Slides
Invited discussant LBA39, LBA40 and abstract 1111O
Presenter: Céleste Lebbé
Session: Melanoma and other skin tumours
Resources:
Slides
3926 - Overall survival (OS) and safety results from a phase 3 trial of ipilimumab (IPI) at 3 mg/kg vs 10 mg/kg in patients with metastatic melanoma (MEL)
Presenter: Paolo Ascierto
Session: Melanoma and other skin tumours
Resources:
Abstract
Slides
4248 - Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma
Presenter: Omid Hamid
Session: Melanoma and other skin tumours
Resources:
Abstract
Slides
Invited discussant abstracts 1106O and 1107O
Presenter: Olivier Michielin
Session: Melanoma and other skin tumours
Resources:
Slides
1679 - Interim safety and efficacy of a randomized (1:1), open-label phase 2 study of talimogene laherparepvec (T) and ipilimumab (I) vs I alone in unresected, stage IIIB-IV melanoma
Presenter: Jason Chesney
Session: Melanoma and other skin tumours
Resources:
Abstract
3426 - Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma
Presenter: Patrick Hwu
Session: Melanoma and other skin tumours
Resources:
Abstract
2400 - Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037
Presenter: Tara Gangadhar
Session: Melanoma and other skin tumours
Resources:
Abstract